title: [Experience in using Аntistax® in patients with lower limb chronic venous insufficiency and accompanying arterial hypertension].
abstract: The main pathogenetic causes of the development of lower limb chronic venous insufficiency (CVI) are associated with hypertension in the inferior vena cava, venous stasis, and ischaemia of the vascular wall. Alterations in microcirculation responsible for the metabolic and trophic processes of the venous wall appear on the background of change in the macrocirculatory bed. A considerable role of the venous endothelial dysfunction was noted. Prescription of phleboprotectors and phlebotonics is of fundamental importance. Efficacy of Antistax makes it possible to recommend its use in combined therapy of various-aetiology and various-grade CVI.
authors.forename: V V
authors.initials: VV
authors.lastname: Sabel'nikov
authors.forename: S I
authors.initials: SI
authors.lastname: Sholkov
mesh_terms: D000328:Adult; D000975:Antioxidants / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D004347:Drug Interactions; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D005260:Female; D005419:Flavonoids / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008833:Microcirculation / Q000187:drug effects*; D008875:Middle Aged; D020011:Protective Agents / Q000494:pharmacology / Q000627:therapeutic use; D011794:Quercetin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014680:Veins / Q000187:drug effects* / Q000503:physiopathology; D014689:Venous Insufficiency / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D000975:Antioxidants; C522873:Antistax; D005419:Flavonoids; D020011:Protective Agents; D011794:Quercetin